Table 1.
KEGG and GO enrichment analysis
| Category | Database | Target genes on category | Expectation value | Enrichment | p value |
|---|---|---|---|---|---|
| Melanoma | KEGG | 17 | 3.7 | 4.6 | 3.10E−06 |
| Bladder cancer | KEGG | 13 | 2.4 | 5.4 | 1.36E−05 |
| Cell cycle | KEGG | 19 | 5.3 | 3.6 | 1.83E−05 |
| Glioma | KEGG | 15 | 3.4 | 4.4 | 1.83E−05 |
| G1_phase(4) & mitotic_G1_phase(5) | GO | 11 | 1.3 | 8.3 | 2.34E−05 |
| Viral carcinogenesis | KEGG | 20 | 6.0 | 3.3 | 2.59E−05 |
| Pancreatic cancer | KEGG | 16 | 4.1 | 4.0 | 2.72E−05 |
| Chronic myeloid leukemia | KEGG | 17 | 4.6 | 3.7 | 3.04E−05 |
| Non-small cell lung cancer | KEGG | 12 | 3.1 | 3.9 | 5.86E−04 |
| p53 signaling pathway | KEGG | 11 | 3.2 | 3.4 | 3.44E−03 |
| Thyroid cancer | KEGG | 6 | 1.4 | 4.3 | 2.67E−02 |
| Biological_phase(2) | GO | 15 | 4.9 | 3.1 | 4.68E−02 |
| Cell_cycle_phase(3)&mitotic_cell_cycle_phase(4) | GO | 15 | 4.6 | 3.3 | 4.68E−02 |
| Cell_maturation(5) | GO | 14 | 4.2 | 3.3 | 4.68E−02 |
| Regulation_of_fibroblast_proliferation(5) | GO | 12 | 3.3 | 3.6 | 4.68E−02 |
| Positive_regulation_of_fibroblast_proliferation(5) | GO | 10 | 2.3 | 4.3 | 4.68E−02 |
| Interphase(4) | GO | 9 | 1.9 | 4.8 | 4.68E−02 |
| Hair_follicle_morphogenesis(4) | GO | 7 | 1.2 | 6.0 | 4.68E−02 |
Significant categories containing at least three times more genes than expected by chance. Provided are the category name, the database where data have been extracted, the number of targets genes of the 63 miRNAs of this category, the expected number of genes given the 2098 background genes, the enrichment factor, and the p value following adjustment for multiple testing